Boehringer Ingelheim Venture Fund related stories
All articles and analysis
German biotech firm Tacalyx snags seed fundingBerlin-based Tacalyx, a biotech company focused on the discovery and development of novel anti-TACA cancer therapies, has secured 7 million euros in seed funding. Boehringer Ingelheim Venture Fund and Kurma Partners led the round with participation from Idinvest Partners, High-Tech Gründerfonds, coparion and Creathor Ventures.
- Rinri Therapeutics lands seed funding
UK-based Rinri Therapeutics, a biotech company, has secured 1.4 million pounds in seed funding. Boehringer Ingelheim Venture Fund and UCB Ventures led the round with participation from BioCity.
- Hookipa Pharma debuts IPO
New York and Austria-based Hookipa Pharma, a developer of immunotherapeutics, has raised $84 million for its IPO after pricing its 6 million shares at $14 per share. The stock began trading April 18, 2019 on the NASDAQ under the ticker symbol “HOOK." BofA Merrill Lynch, SVB Leerink and RBC Capital Markets are the lead underwriters. Hookipa's pre-IPO backers included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.
- Belgian biotherapeutics firm AgomAb inks Series A funding
AgomAb, a Belgian biotherapeutics company, has secured 21 million euros in Series A funding. V-Bio Ventures and Advent France Biotechnology led the round with participation from Boehringer Ingelheim Venture Fund, Omnes and Pontifax.
- Boehringer Ingelheim acquires ViraTherapeutics for $245 mln
Boehringer Ingelheim has acquired Austria-based ViraTherapeutics, a developer of virus-based immunotherapeutics for the treatment of cancer, for $245 million. ViraTherapeutics was a portfolio company of EMBL Ventures.
High-Tech Gründerfonds raises €316.5mThe German venture capital firm closes latest fund above target.
- Acousia Therapeutics raises 10 mln euros
Acousia Therapeutics said May 14 that it raised 10 million euros ($11.9 million) in a Series B round led by LBBW Venture Capital and joined by new investors Creathor Ventures and Bregua Corp. Boehringer Ingelheim Venture Fund (BIVF) and Kreditanstalt für Wiederaufbau also participated in the round. Acousia, of Tubingen, German, is developing therapies for inner ear-related diseases and pathologies.
- Belgian biotech company Rewind Therapeutics picks up Series A funding
Rewind Therapeutics, a Belgian biotech company, has closed 15.2 million euros in Series A financing. The backers were Boehringer Ingelheim Venture Fund, Merck Ventures BV, Participatiemaatschappij Vlaanderen, KU Leuven's Centre for Drug Design and Discovery and KU Leuven Gemma Frisius Fonds.
- Hookipa Biotech scores $59.6 mln Series C
Hookipa Biotech AG, an Austrian clinical stage biotech company, has raised $59.6 million in Series C financing. The investors included HBM Partners, Hillhouse Capital, Sirona Capital, Gilead, Sofinnova Partners, Forbion Capital Partners, Boehringer Ingelheim Venture Fund, Takeda Ventures and BioMedPartners.
- Merck to buy VC-backed Rigontec
Merck has agreed to acquire Germany-based Rigontec, which focuses on RIG-I targeting RNA therapeutics. According to terms of the deal, Merck will make an upfront cash payment of 115 million euros to Rigontec’s shareholders. Also, based on the fulfillment of certain milestones, Merck may make additional contingent payments of up to 349 million euros. Rigontec is backed by Boehringer Ingelheim Venture Fund, Forbion Capital Partners, High-Tech Gründerfonds, MP Healthcare Venture Management, NRW.BANK, Sunstone Capital and Wellington Partners Life Sciences.